| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20043039 | HPV | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS20017882 | HPV | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS20022727 | HPV | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS20037024 | HPV | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44009397 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44028155 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44030108 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44021446 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44027833 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44033068 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | APP |
|---|---|
| DrugBank ID | DB12274 |
| Drug Name | Aducanumab |
| Target ID | BE0003392 |
| UniProt ID | P05067 |
| Regulation Type | antagonist |
| PubMed IDs | 29686315; 33199898; 27582220 |
| Citations | Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, Walz T, Pepinsky RB, Bussiere T, Hamann S, Cameron TO, Weinreb PH: Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta. Sci Rep. 2018 Apr 23;8(1):6412. doi: 10.1038/s41598-018-24501-0.@@Uhlmann RE, Rother C, Rasmussen J, Schelle J, Bergmann C, Ullrich Gavilanes EM, Fritschi SK, Buehler A, Baumann F, Skodras A, Al-Shaana R, Beschorner N, Ye L, Kaeser SA, Obermuller U, Christensen S, Kartberg F, Stavenhagen JB, Rahfeld JU, Cynis H, Qian F, Weinreb PH, Bussiere T, Walker LC, Staufenbiel M, Jucker M: Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nat Neurosci. 2020 Dec;23(12):1580-1588. doi: 10.1038/s41593-020-00737-w. Epub 2020 Nov 16.@@Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A: The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
